J R Eckler
Overview
Explore the profile of J R Eckler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reissig C, Eckler J, Rabin R, Rice K, Winter J
Pharmacol Biochem Behav
. 2007 Oct;
88(3):312-7.
PMID: 17936346
A previous investigation in our laboratory found that the stimulus effects of the 5-HT2A agonist, LSD, are potentiated by 5-HT1A receptor agonists including the prototypic agonist, 8-OH-DPAT. Also suggestive of...
2.
Fantegrossi W, Harrington A, Kiessel C, Eckler J, Rabin R, Winter J, et al.
Pharmacol Biochem Behav
. 2006 Feb;
83(1):122-9.
PMID: 16460788
Few studies have examined the effects of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) in vivo. In these studies, 5-MeO-DIPT was tested in a drug-elicited head twitch assay in mice where it was compared to...
3.
Reissig C, Eckler J, Rabin R, Winter J
Psychopharmacology (Berl)
. 2005 Jul;
182(2):197-204.
PMID: 16025319
Rationale: It has been suggested that the 5-HT1A receptor plays a significant modulatory role in the stimulus effects of the indoleamine hallucinogen lysergic acid diethylamide (LSD). Objective: The present study...
4.
Winter J, Kieres A, Zimmerman M, Reissig C, Eckler J, Ullrich T, et al.
Pharmacol Biochem Behav
. 2005 Jul;
81(4):830-7.
PMID: 16005500
Rationale: Drug-induced stimulus control has proven to be a powerful tool for the assessment of a wide range of psychoactive drugs. Although a variety of species has been employed, the...
5.
Winter J, Eckler J, Rice K, Rabin R
Pharmacol Biochem Behav
. 2005 Jun;
81(3):694-700.
PMID: 15970314
Previous investigations in our laboratory have found that the stimulus effects of the hallucinogenic serotonergic agonists DOM and LSD are potentiated by phencyclidine [PCP], a non-competitive NMDA antagonist. Also suggestive...
6.
Eckler J, Reissig C, Rabin R, Winter J
Pharmacol Biochem Behav
. 2004 Sep;
79(1):25-30.
PMID: 15388280
Previous studies conducted in our laboratory have shown that acute administration of the selective serotonin re-uptake inhibitor (SSRI), citalopram, potentiates the stimulus effects of the phenethylamine hallucinogen [-]-2,5-dimethoxy-4-methylamphetamine (DOM) in...
7.
Winter J, Eckler J, Rabin R
Psychopharmacology (Berl)
. 2003 Nov;
172(2):233-40.
PMID: 14598016
Rationale: On the basis of electrophysiological evidence, it has been proposed that both antagonism of NMDA receptors by drugs such as PCP and stimulation of 5- HT(2A) receptors by drugs...
8.
Eckler J, Chang-Fong J, Rabin R, Smith C, Teitler M, Glennon R, et al.
Pharmacol Biochem Behav
. 2003 Sep;
75(4):845-52.
PMID: 12957227
The present investigation was undertaken to test the hypothesis that known metabolites of the phenylethylamine hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) are pharmacologically active. This hypothesis was tested by evaluating the ability of...
9.
Eckler J, Rabin R, Winter J
Pharmacol Biochem Behav
. 2003 Jul;
75(2):405-10.
PMID: 12873632
Nefazodone is presently marketed as an antidepressant that inhibits both serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine reuptake while antagonizing pirenpirone (5-HT2) receptors. This 5-HT receptor type is believed to play a...
10.
Winter J, Eckler J, Doat M, Rabin R
Pharmacol Biochem Behav
. 2002 Oct;
74(1):95-101.
PMID: 12376156
Previous reports from our laboratory have provided evidence that acute, i.e., concurrent, treatment with selective serotonin reuptake inhibitors (SSRIs) augments the stimulus effects of indoleamine and phenethylamine hallucinogens in the...